Market Brief

The articles are produced in Chinese only.

Author

劉智健先生 (CK Lau)
助理經理

股票研究投資經驗豐富。利用市場數據、技術走勢及投資氣氛用來分析市況,配合合適的投資工具,為客戶評估風險提供買賣策略。喜歡研究資源類及內需類股票 。
Phone:
2943 7499

山東新華製藥股份 0719.HK,首三季純利2.93億元人民幣升2.8%

Friday, December 2, 2022 Views5326

公司概覽

主要從事開發、製造和銷售化學原料藥、製劑、醫藥中間體及其他產品。

 

截至2022年9月30日止首三季業績(未經審核)

營業收入約為人民幣(下同)54.53億元,同比增加 10.39%。

歸屬於上市公司股東的淨利潤: 2.93億元,同比增加 2.84%。

每股基本盈利為0.45元。

 

業務概覽

  • 上半年集團克服疫情、國際市場動盪、原材料價格上漲、市場競爭加劇等諸多不利因素影響,狠抓市場開拓,科學組織生產,加大研發力度,積極推進項目建設,企業保持了穩定的發展態勢。
  • 保障市場需求,發揮營銷龍頭帶動作用:
  • 針對疫情管控要求,採取切實可行辦法,上半年重點暢銷產品及新產品均實現了增產,有力保障了市場需求。
  • 科技創新取得新成果:
  • 上半年共取得5個新產品批件,2個一致性評價批件,2個原料藥文號,獲得授權專利3件。抗AD創新藥物OAB-14等重點創新藥物研發有序推進。
  • 重點建設項目有序推進:
  • 基礎管理持續深化不斷加強:
  • 嚴格落實疫情防控措施,公司保持零感染。生命線工程運行穩定,上半年無一般及以上安全環保質量事故發生。

 

未來展望

受國際形勢及疫情影響,下半年本集團主導原料藥產品面臨的市場競爭更加激烈,但本集團亦將採取切實可行的措施,確保產品出口總體穩定。隨著本集團特色原料藥保持快速發展,製劑戰略品種市場份額不斷提高,製劑合作項目落地和商業化生產快速推進,企業新的增長點正在形成,發展後勁持續增強。

1. 強化生產保障,全力降本增利,嚴控費用支出

2. 加快推進新品研發和技術進步

3. 加快推進重點項目建設,儘快實現達產達效

 

山東新華製藥股份(00719)昨日收市價,5.34元,

11月份開始成交配合上升, 以前阻力位為參考, 參考目標價為HK$6.39。
 

*資料來源: 集團公告

 

如有查詢 請聯繫Mr CK LAU

辦公室電話: 29437499

電郵: chikinlau@phillip.com.hk

December 1, 2022

註:本人劉智健為證監會持牌人士。截至本評論文章發表日止,本人及/或其有聯繫者並無持有全部提及之証券的所有相關財務權益。

 

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
E-Check
Login
Investor Notes
Free Subscribe
Contact Us